Latest Multiple Myeloma Research Foundation Stories
In early results, all participants responded to treatment with limited side effects ANN ARBOR, Mich., Dec.
A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients.
In the news release, Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study, issued 07-Dec-2010 by Onyx Pharmaceuticals, Inc.
EMERYVILLE, Calif., Dec. 7, 2010 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
ORLANDO, Fla., Nov.
Bio-Gal is Developing a Drug for the Treatment of Multiple Myeloma ("MM") Patients - Research and Clinical Observations of MM Terminal Patients by Bio-Gal Suggests That Treatment with Erythropoietin Suppresses the Disease, Prolonging and Improving the Patients' Lives. - XTL is Commencing Preparations to Begin a Phase 2 Clinical Trial in Multiple Myeloma Patients - Under the Transaction, XTL Received $1.5 Million in Cash XTL has announced that their purchase...
EMERYVILLE, Calif., July 26 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
Dr. Brian G.M. Durie, co-founder and chair of the International Myeloma Foundation (IMF), heads consortium of investigators across U.S. LOS ANGELES, April 12 /PRNewswire-USNewswire/ -- Aptium Oncology, Inc.
QUEBEC CITY, March 1 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
Trial conducted pursuant to Special Protocol Assessment with the Food and Drug Administration QUEBEC CITY, Dec. 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
- A serpent whose bite was fabled to produce intense thirst.